Samsung Biologics Announces Schedule for First Half 2026 Earnings Release


  • Samsung Biologics has announced that its first half 2026 earnings results will be disclosed on July 23, 2026.
  • The financial figures have not yet been released, and the scheduled date may change due to company circumstances.
  • [AI Summary]This disclosure is a procedural notice of the earnings release schedule, with no immediate impact on shareholder value confirmed. Investment decisions should be made after the actual results are released.

KOSPI Filing Information


  • Notice of Disclosure of Settlement Results (Informational Disclosure)
  • Company: Samsung Biologics (207940)
  • Submission: Samsung Biologics Co., Ltd.
  • Under KRX KOSPI Market Division

  • Shares: 46,290,951
  • Price: 1,363,000 KRW
  • Market Cap: 63,094.6 B KRW